Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging.
Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. giovanni.paganelli@irst.emr.it.
Giovanni
G
Paganelli
Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Maddalena
M
Sansovini
Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Emanuela
E
Scarpi
D006801:Humans; D018358:Neuroendocrine Tumors; D015282:Octreotide; D011868:Radioisotopes; D018000:Receptors, Peptide
D011868:Radioisotopes; D018000:Receptors, Peptide; D015282:Octreotide